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Ion channel trafficking and gating are often influenced by
interactions with auxiliary subunits. Tetratricopeptide repeat-
containing Rab8b-interacting protein (TRIP8b) is an auxiliary
subunit for neuronal hyperpolarization-activated cyclic nucle-
otide-gated (HCN) channels. TRIP8b interacts directly with two
distinct sites of HCN channel pore-forming subunits to control
channel trafficking and gating. Here we use mutagenesis com-
bined with electrophysiological studies to define and distin-
guish the functional importance of the HCN/TRIP8b interac-
tion sites. Interaction with the last three amino acids of the
HCN1 C terminus governed the effect of TRIP8b on channel
trafficking, whereas TRIP8b interaction with the HCN1 cyclic
nucleotide bindingdomain (CNBD) affected trafficking andgat-
ing. Biochemical studies revealed that direct interaction
between TRIP8b and the HCN1 CNBD was disrupted by cAMP
and that TRIP8b binding to the CNBD required an arginine res-
idue also necessary for cAMP binding. In accord, increasing
cAMP levels in cells antagonized the up-regulation of HCN1
channels mediated by a TRIP8b construct binding the CNBD
exclusively. These data illustrate the distinct roles of the two
TRIP8b-HCN interactiondomains and suggest thatTRIP8band
cAMPmaydirectly compete for binding theHCNCNBD to con-
trol HCN channel gating, kinetics, and trafficking.
HCN3 channels are encodedby theHCN1–4 gene family and
mediate hyperpolarization-activated cation current, Ih, which
plays an important role in regulating electrical activity of neu-
rons (for review, see Refs. 1–3). HCN channel gating and traf-
ficking to specific subcellular domains contribute critically to
the multiple physiological roles of the channels, and regulation
of these processes is important for normal physiological func-
tions as well as in disease (4). Each pore-forming HCN subunit
is composed of an intracellular N terminus, six transmembrane
domains, and a large intracellularC-terminal tail that includes a
group of 6 helices (A-F, C-linker) that links the transmem-
brane domains to a cyclic nucleotide binding domain (CNBD).
Direct binding of cyclic nucleotides to the CNBD of HCN sub-
units facilitates channel availability by opening of channels at
more physiological (less hyperpolarized) potentials and by
speeding kinetics of activation (5–7).
In addition to being regulated by cAMP, HCN channels
interact with numerous proteins that can influence their func-
tion (for review, see Ref. 8). Recent studies have demonstrated
that in the brain, native HCN channels co-purify with TRIP8b
(also called peroxin 5-like protein, PEX5L) (9), and consistent
with a role as an auxiliary HCN channel subunit, TRIP8b regu-
lates HCN channel trafficking, voltage gating, and kinetics in
vitro and in vivo (9–11). The TRIP8b C terminus is highly
homologous to the peroxisomal import protein, peroxin 5
(PEX5), and is comprised of two sets of three tetratricopeptide
repeat (TPR) domains separated by a linker, a C-terminal tail,
and a region enriched in acidic amino acids N-terminal to the
first TPR set that is conserved in both PEX5 and TRIP8b (10,
12). The N terminus of TRIP8b shares no sequence homology
to PEX5 and is subject to extensive alternative splicing that
leads to expression of multiple distinct TRIP8b isoforms. We
previously showed that the TRIP8b TPR sets together interact
with theHCN1C-terminal tripeptide, whereas a region including
the conserved acidic domain and the first two TPR domains is
required for independent interaction with the HCN1 channel
C-linker and CNBD (10). Alternatively spliced TRIP8b isoforms
differentially affect surface expression and thereby control HCN
channel current density, whereas all TRIP8b isoforms exhibit neg-
ative regulation on channel gating and kinetics (10, 11).
Whether the distinct interaction sites are responsible for dis-
tinct functional effects of TRIP8b on HCN channels is
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unknown. Because interactions betweenPEX5 and cargoC-ter-
minal tripeptides are important for translocating PEX5 cargo
from the cytoplasm to the peroxisomal matrix, we suspected
that the interaction between the TRIP8b TPR domains and the
HCNsubunit C-terminal tripeptides could be important for the
trafficking effects of distinct TRIP8b isoforms. The effects of
TRIP8b onHCNchannel gating and kinetics are the opposite of
the effects of cAMP, and indeed TRIP8b reversibly blocks
cAMP effects on HCN2 channel function (9). Whereas we
found direct interaction between TRIP8b and the HCN1
C-linker and CNBD, it has remained unknown if TRIP8b and
cAMP compete for the same site on the CNBD. In this study we
address the distinctive roles of the two interaction sites of
TRIP8b and HCN channels using biochemical, cell biological,
and electrophysiological approaches.
EXPERIMENTAL PROCEDURES
Cloning—All restriction enzymes were purchased from New
England Biolabs. All oligonucleotides for use in PCR amplifica-
tion and oligo insertion were synthesized by Integrated DNA
Technologies (Coralville, IA). The proper introduction of all
mutations and deletions was verified by DNA sequencing.
Nomenclature of Constructs and Mutations—To simplify
naming of TRIP8b constructs, we now prefer the naming sys-
tem used by Santoro et al. (11) for TRIP8b alternatively spliced
isoforms. Thus, TRIP8b_IsoA2 described in Lewis et al. (10) is
TRIP8b(1a-2-4) (11), wherein 1a-2-4 indicates inclusion of
alternatively spliced exons 1a, 2, and 4. Furthermore, because
different N-terminal splice isoforms all have different residue
numbering in the conserved TPR domains, we introduced a
naming scheme that identifies mutations based on the sequen-
tial number of the TRIP8b TPR domain (1–6) and the amino
acid residue number (1–34) within that specific TPR domain.
Thus, a mutation of Asn-13 of TPR domain 3 to Ala in any
TRIP8b isoform is indicated with the designation “TPR3-
N13A.” In TRIP8b(1a-2-4), for example, this mutation is repre-
sented as TRIP8b(1a-2-4)[TPR3-N13A].
cDNA Plasmids—The yeast two-hybrid and mammalian
expression constructs of HCN1, HCN1-HA, and wild type
TRIP8b were described previously (10). Point mutations in
TRIP8b were introduced in pGAD-TRIP8b(1c). First, using
two-part PCR to generate overlapping fragments, a silent XbaI
site was introduced in exons encodingTPR2-C27 and -L28, and
then a silent AgeI site was introduced in exons encoding TPR5-
R16 and -S17. TPRdomainmutationswere introduced into this
new TRIP8b(1c) clone containing silent XbaI and AgeI sites by
PCR mutagenesis using primers and restriction enzyme sites
listed in Table 1. pXEC-TRIP8b(1a-2-4)[TPR3-N13A] was
made by inserting the EcoRV/BamHI fragment from pGAD-
TRIP8b(1c)[TPR3-N13A] into pXEC-TRIP8b(1a-2-4) at the
same sites. A construct containing the 58 mutation was made
by generating a PCR fragment encoding residues 20–220 of
TRIP8b(1a-2-4) and inserting this at the NcoI/EcoR I sites of
fragment pGAD-TRIP8b(1c) to make pGAD-TRIP8b(1a-2-
4)[58]. pXEC-TRIP8b(1a-2-4)[58] and pXEC-TRIP8b(1a-2-
4)[58TPR3-N13A] weremade by inserting the BglII/EcoRV
fragment from pGAD-TRIP8b(1a-2-4)[58] into pXEC- TA
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TRIP8b(1a-2-4) or pXEC-TRIP8b(1a-2-4)[TPR3-N13A],
respectively.
For CNBD yeast two-hybrid constructs, template plasmids
encoding mouse HCN1 and HCN2 were provided by Steven
Siegelbaum. Template plasmids encoding mouse HCN3 and
human HCN4 were provided by Martin Biel (Universita¨t
Mu¨nchen). Template plasmids encoding rat CNG2, CNGA4,
sea urchin SpIH, andmouse KCNH1 (ether-a-go-go) were pro-
vided byWilliamZagotta (University ofWashington). Plasmids
encoding human CNGA3 and CNGB3 were provided by K.-W.
Yau (Johns Hopkins) and Michael Varnum (Washington State
University), respectively. cDNA fragments SpIH(470–655) and
KCNH1(505–702) were cut from parent plasmid pMAL-C2T
with HindIII (blunted with Klenow), and NcoI was then
inserted into yeast two-hybrid bait vector pGBK-T7 at NcoI/
SmaI. Other CNBD clones were obtained by PCR of the parent
plasmids to amplify cDNA encoding the CNBD plus 17 N-ter-
minal and 4 C-terminal amino acids followed by subcloning
into yeast two-hybrid bait vector pGBK-T7. Table 2 lists the
primers and restriction sites used.
TRIP8b Protein Expression Constructs—cDNA encoding
TRIP8b(1a) and TRIP8b(1c) were cloned into pETM30 at
Nco1/Xho1.
Yeast Two-hybrid Assays—Directed yeast two-hybrid inter-
action assays were performed as previously described (13).
Co-Immunoprecipitation Assays—Co-immunoprecipitation
of HCN and TRIP8b from transfected human embryonic kid-
ney 293 (HEK293T) cells (ATCC) and surface HA-tagged
HCN1 immunoprecipitation were performed as described pre-
viously (10).
Preparation of Purified GST Fusion Proteins—Fusion protein
was expressed in BL21 bacteria (Stratagene) and purified by
glutathione-Sepharose affinity chromatography (Amersham
Biosciences) according to manufacturer’s instructions. Protein
was quantified by Coomassie Plus Protein Assay Reagent
(Thermo), separated into aliquot, and stored at20 °C.
GST Pulldown Assays—HEK293 cells were transfected with
cDNA plasmids encoding HCN1, HCN1[3], HCN1[R538E],
or HCN1[3R538E] and lysed in TEEN-Tx (TEEN buffer (50
mM Tris-HCl, pH 7.4, 1 mM EDTA, 1 mM EGTA and 150 mM
NaCl) containing 1% Triton X-100) as described above. After
removal of an input fraction, 5 mg of GST-tagged TRIP8b
fusion protein was added along with glutathione-Sepharose
beads, and the reaction was gently rocked for 2 h at 4 °C. Super-
natant was then removed, and beads were washed six times
with cold TEEN-Tx followed by the addition of 4 sample
buffer and boiling to elute bound proteins. For some experi-
ments, 8-bromoadenosine 3:5-cyclic monophosphate or
adenosine 3:5-cyclic monophosphate (Sigma) was added to
the pulldown reaction mixture. IC50 was calculated using
GraphPad Prism software.
Western Blotting—Western blotting was performed as previ-
ously described (14). Primary antibody concentrations used
were gp anti-HCN1 (1:3000) and gp anti-TRIP8b (1:3000), and
the concentrations of secondary horseradish peroxidase-conju-
gated rabbit anti-gp antibody were 1:10,000. Densitometric
quantization of band intensitywas performedusing Photoshop.
Statistical analyses were performed by ANOVA using
GraphPad Prism software, and the significance of intergroup
differences was determined using 1-way ANOVAwith Tukey’s
post hoc test. Differences at the level of p  0.05 were consid-
ered statistically significant.
Flow Cytometry—The surface expression evaluation by flow
cytometry was performed as described previously (9). HEK293
cells were transfected with HA-HCN1 and TRIP8b(1a-2-4)
wild type and mutations with cell transfected with pEGFP as a
control. For the cAMP studies, cells were incubated with 100
M forskolin (Sigma) for 1 h after 72 h of transfection. Nonper-
meabilized cells were stained with mouse anti-HA primary
antibody to label surface HA and then were stained with sec-
ondary antibody conjugated to Alexa-647 (Invitrogen). Cells
were run in a Cyan ADP flow cytometer (Dakocytomation) at
theNorthwesternUniversity FlowCytometry Core facility, and
data were analyzed by FloJo software. The presented fluores-
cence index was calculated as the integral of the Alexa-647 flu-
orescence with respect to cell number, which was normalized
by eGFP-positive cells in each transfection condition. The flu-
orescence indices for each condition were normalized to the
control transfection condition (HCN1 plus eGFP). Statistical
analyses were performed using 1-way ANOVA with Tukey’s
post hoc-test.
Electrophysiological Measurements in HEK293 Cells—
HEK293 cells for electrophysiological measurements were
grown and maintained as previously described (15). 1–2 days
TABLE 2
CNBD constructs
cDNA 5 Primer 3 Primer
Cloning
sites
pGBK-T7-HCN1-(453–591) CGC GAA TTC TTC AAC TGC CGG AAA CTG
G
CGG GGA TCC TCA CAG GAG AAT AGA GTT EcoRI/BamHI
pGBK-T7-HCN2-(439–644) CGC GAA TTC ATC CAG TCC CTG GAT TCG
TC
CGC GGA TCC GTC GAC TCA CAG CAA GAT
GGA GTT CTT CTT G
EcoRI/BamHI
pGBK-T7-HCN3-(349–554) CGC AAG CTT GTC GAC CTA TCC AGT CCC
TGG ACT CTT CC
CGC GGT ACC GCG GCC GCT CAC TGC AGT
ATC GAA TTC TTT TTG CCG
SalI/NotI
pGBK-T7-HCN4-(517–722) CGC GAA TTC ATC CAG TCC CTG GAC TCC
TCC CGG
CGC AAG CTT GTC GAC TCA GAG GAG GAT
GGA GTT CTT CTT GCC
EcoR I/SalI
pGBK-T7-CNGA2-(380–583) CTC CAC CAT GGA TGC CAC ACG AGC AG ATA TAT GGA TCC TCA TTC CTT CAT CAG
GAT CTC
NcoI/BamH1
pGBK-T7-CNGA3-(471–612) CGC GAA TTC AAC GTG CAC CTG GAC ACG CGC GGA TCC CGG GTC AGA TCA GGT TGT
CTT TCA TC
EcoRI/BamHI
pGBK-T7-CNGA4-(272–475) CGC GCG CCA TGG ACA CTG CAG ATG CGG
CCT TC
ATA TAT GGA TCC TCA CAT TTT AAG CAA
GAT TTC
NcoI/BamH1
pGBK-T7-CNGB3-(513–652) CAT ATG GCC ATG GAC GAT GTG AAC TTC
AGC ATC
CGC GGA TCC CGG GTC AGG TCT TAG CCT
TCT GC
NcoI/BamH1
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before transfection, cells were trypsinized and re-plated on
12-mm glass coverslips at 50–60% density. Transfection with
plasmid cDNA was performed 2–3 days after plating using the
calcium-phosphate precipitation method. A vector encoding
the wild type mouse HCN1 channel was co-transfected with
various TRIP8b constructs at a 1:1 ratio (0.6 g of DNA per
construct per coverslip) alongside a vector encoding eGFP (0.06
g/coverslip) to visualize transfected cells.
Whole-cell patch clamp recording was performed 24–48 h
post-transfection. A coverslip containing transfected HEK293
cells was placed in a bath chamber of an inverted Olympus
IX-70 microscope and was continuously perfused with an
extracellular solution containing 110 mM NaCl, 5 mM KCl, 2
mM CaCl2, 1 mM MgCl2, and mM 10 HEPES (pH set to 7.30).
Recording pipettes were pulled from borosilicate glass and had
a resistance of 2–4 megaohms when filled with an intracellular
solution containing 105mMpotassium gluconate, 30mMKCl, 2
mM Mg-ATP, 5 mM EGTA, 0.5 mM CaCl2, and 10 mM HEPES
(pH set to 7.30). Series resistance was15 megaohms and was
compensated for at least 70%. Under these conditions, voltage
errors originating from uncompensated series resistance were
in almost all cases lower than 1mVandnever higher than 2mV.
Whole-cell voltage clamp was realized with an Axopatch
200B amplifier (Molecular Devices) controlled by a custom-
made program written in MATLAB (Mathworks). Currents
were low-pass Bessel filtered at 2 kHz. The currents were sam-
pled at 5 kHz by a custom-made program written in MATLAB
that also controlled the amplifier and generated the voltage
commands. Voltages were offline corrected for liquid junction
potentials (calculated as 13 mV).
Ih was evoked by a series of hyperpolarizing steps from a
holding potential of 40 to 130 mV in decrements of 10
mV. Analysis of electrophysiological data was performed using
custom-written procedures in MATLAB. The amplitude of Ih
was quantified as the difference between the current measured
immediately after the beginning of the hyperpolarizing step and
the steady state current determined at the end of the pulse.
Current density was calculated using the cell capacitance as
read from the compensation dial on the amplifier. The cell
capacitance (quantified at 14.4	 0.4 picofarads, n
 111 cells)
did not differ across the various experimental conditions (one-
way ANOVA).
Activation kinetics were best fit to a single exponential func-
tion, and all current traces included in the final analysis had a
goodness-of-fit value above 0.98.We investigatedwhether add-
ing a second or third exponential to the fit would lead to a
considerable improvement of the fit, but this was hardly ever
the case in our preparation. As would have complicated statis-
tical comparison, we did not include these results in the further
analysis.
The voltage-dependent current as measured above results
from the voltage-dependent activation and the driving force as
best described by the Goldman-Hodgkin-Katz equation,
IV  gV  V 
Ion]in
[Ion]out
 expV
1 expV
(Eq. 1)
with  
 F/RT, where g(V) is the voltage-dependent conduct-
ance of Ih, F the Faraday constant, R the gas constant, and T
represents the absolute temperature; for Ionin and Ionout we
used concentrations that yielded the correct Nernst equilib-
rium potential for Ih (Erev
36mV). The voltage dependence
of g(V) was well described by a Boltzmann equation,
gV 
gmax
1  expv vSDvs 
(Eq. 2)
where gmax is themaximal conductance,V is the holding poten-
tial, V50 is the voltage of half-maximal activation, and Vs is a
slope factor (in mV).
All data points are given as the means	 S.E. Statistical com-
parison between groups was performed using an ANOVA fol-
lowed by a Dunnett post-hoc test or by the non-parametric
Kruskal-Wallis ANOVA with multiple testing using Dunn-
Sidak correction. Statistical analysis was performed using SPSS
software (Version 18.0, SPSS Inc.) andMATLAB. p 0.05 was
considered to indicate a significant difference.
RESULTS
Two Distinct Interaction Domains of TRIP8b and HCN1—In
previous work, we demonstrated that TRIP8b interactions with
HCN1 occur at distinct sites in both TRIP8b and HCN1 (10).
Binding to the C-terminal tripeptide of HCN1 (SNL) required
the C-terminal portion of TRIP8b, including both sets of TPR
domains. Additionally, we found a second interaction site with
HCN1 that required a 58-amino acid segment in the N termi-
nus upstream of the TPR sets. This second binding domain
interacted with an HCN1 construct containing only the intra-
cellular C-linker and cyclic nucleotide binding domain (HCN1-
(386–591); HCN1-CNBD). We performed a further deletion
of 4–6 of the C-linker helices (HCN1-(453–591); HCN1-
CNBD) and found that an intact CNBD, but not C-linker, is
required for this interaction (Fig. 1A). For clarity, we refer to
these two interactions hereafter in this manuscript as NC (for
TRIP8b N terminus, HCN CNBD) and TT (for TRIP8b TPR
domains, HCN Tripeptide).
To evaluate the structural architecture of these distinct inter-
action sites, we performed mutagenesis to disrupt NC or TT
interactions in a full-length TRIP8b isoform known to dramat-
ically up-regulate HCN1, TRIP8b(1a-2-4). As a preliminary
screen we utilized directed yeast two-hybrid screens to charac-
terize effects of mutations in disrupting either NC or TT inter-
actions. We found that wild type TRIP8b(1a-2-4) interacted
with HCN1 C-terminal fragments containing the C-terminal
tripeptide (with no CNBD) or the CNBD (with no tripeptide)
(Fig. 1A). Wild type TRIP8b(1a-2-4) also interacted with frag-
ments containing either theC-terminal tripeptide or theCNBD
fromHCN2,HCN3, andHCN4, indicating both theNCandTT
interactions occur with all HCN isoforms. We next made a
full-length TRIP8b(1a-2-4) construct containing a deletion of
the 58 amino acid residues upstream of the TPR domains
required for the HCN1 NC interaction, TRIP8b(1a-2-4)[58].
TRIP8b(1a-2-4)[58] did not interact with any HCN CNBD
but did interact with all HCN subunit constructs containing the
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C-terminal tripeptide (Fig. 1A). Thus, the mutation of
TRIP8b(1a-2-4)[58] selectively eliminates interaction with
the HCN(1–4) CNBD.
We next sought to createmutations in TRIP8b to disrupt the
TT interaction with the HCN subunit C-terminal tripeptide.
We took advantage of the homology of TRIP8b and PEX5 com-
bined with the knowledge of PEX5 structure (12) and extensive
information about functional mutagenesis (16, 17) to design
TRIP8b constructs predicted to disrupt binding to the terminal
three amino acids (SNL). By aligning TRIP8b and PEX5
sequences, residues that are important for PEX5binding to SKL
were identified in TRIP8b (supplemental Fig. 1). We then cre-
ated PEX5 homologousmutations in full-length TRIP8b. Using
yeast two-hybrid assays, we identified four point mutations in
four distinct TRIP8b TPR domains that disrupted TT interac-
tion (TPR2-E15K, TPR3-N13A, TPR5-N5K, and TPR6-R2A),
none of which affected binding to HCN constructs containing
the CNBD (Fig. 1A). The PEX5 C-loop at the C terminus after
the TPR domains is important for some PEX5 cargo binding
(12), and we similarly found that deletion of the TRIP8b resi-
dues C-terminal to the sixth TPR domain also disrupted HCN
tripeptide binding (data not shown). We next generated a
FIGURE 1. TRIP8b interacts with HCN channels at two distinct sites. A, schematic representations of HCN subunit and TRIP8b constructs tested in directed
yeast two-hybrid interactions are shown. The  indicates auxotrophic growth resulting from interaction of bait and prey plasmids, whereas 0 signifies no
interaction. B, Western blots of extracts from HEK293T cells transfected with HCN1 and the indicated TRIP8b constructs were immunoprecipitated with
-TRIP8b and probed with -HCN1 (top panels) or -TRIP8b (bottom panels). Input is 6% that of the total lysate, whereas immunoprecipitate (IP) is 15%.
Molecular mass markers are shown in kDa. C, shown are summary data for interaction of HCN1 and TRIP8b. ** and ***, p 0.01 and 0.001, respectively, versus
TRIP8b(1a2–4), 1-way ANOVA with Tukey’s post hoc test, n
 3).
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TRIP8b construct with mutations predicted to completely dis-
rupt interactions with HCN subunits. As shown in Fig. 1A, the
double mutant construct TRIP8b(1a-2-4)[58TPR3-N13A]
was unable to interact with CNBD- or tripeptide-containing
HCN constructs in yeast two hybrid assays. The interaction
between TRIP8b mutations and HCN1 was next verified by
coimmunoprecipitation in HEK293T cells. Consistent with yeast
two-hybrid data, wild type TRIP8b(1a-2-4) coimmunoprecipi-
tated robustly with HCN1. Furthermore, both TRIP8b(1a-2-
4)[58] and TRIP8b(1a-2-4)[TPR3-N13A] immunoprecipi-
tated HCN1. As predicted, coimmunoprecipitation was
abolished in the TRIP8b construct harboring both mutations,
TRIP8b(1a-2-4)[58TPR3-N13A] (Fig. 1, B and C).
Interaction with Both the CNBD and the C-terminal Tripeptide
of HCN1 Contribute to TRIP8b Regulation of Ih Density—Acting
as an auxiliary subunit of the HCN channel complex, TRIP8b
interaction influences channel current density and gating
(9–11). Utilizing our TRIP8b constructs harboring specific
defects in HCN subunit binding, we sought to determine which
binding sites between TRIP8b and HCN subunits contributed
to this function. We first evaluated TRIP8b effects on current
density. Expression of HCN1 alone in HEK293 cells resulted in
a mean current density of 7.4	 1.7 pA/pF (measured at110
mV, n
 24, Table 3, Fig. 2). Co-expression of HCN1 with wild
type TRIP8b(1a-2-4), a TRIP8b isoform that dramatically up-
regulates HCN current (10), markedly enhanced current den-
sity (33.8	 5.4 pA/pF, p 0.001, Table 3, Fig. 2). Transfection
of TRIP8b(1a-2-4) harboring the 58 mutation also signifi-
cantly up-regulated current density as compared with HCN1
alone (24	 4.3 pA/pF, n
 17; Table 3, Fig. 2), but values were
lower than those obtained with full-length TRIP8b(1a-2-4).
Interestingly, expression of HCN1 with the TRIP8b(1a-2-
4)[TPR3-N13A] mutant resulted in an intermediate current
density with values comparable with those obtained with the
TRIP8b(1a-2-4)[58] mutant (19.4	 4.3; n
 25; Table 3; Fig.
2). Co-transfection of the double mutant TRIP8b(1a-2-
4)[58TPR3-N13A], which cannot interact with either the
CNBD or the C-terminal tripeptide domain of HCN1, gener-
ated an HCN1 current density that was comparable with that
found with HCN1 alone (9.2 	 0.9 pA/pF, n 
 22, p  0.05,
Table 3, Fig. 2). These results suggest that interaction between
TRIP8b and both the CNBD and the C-terminal tripeptide SNL
contribute to the TRIP8b effect on HCN current.
TRIP8b Interaction with CNBD or C-terminal Tripeptide
Regulates Current Density through the Effects on HCN Channel
Trafficking—TRIP8b controls current density via regulation of
HCN1 surface expression (10, 11). Therefore, we expected that
the 58 and TPR3-N13A mutants, both enhancing current
density, would also enhance surface expression. To measure
surface expression, we performed flow cytometry using non-
FIGURE 2.TRIP8b interactionwith theHCN1CNBDand theC-terminal tripeptide contribute to TRIP8b-mediated increases inHCN1 current density.A,
example Ih traces recorded from transfectedHEK293 cells in response to a series of hyperpolarizing steps (from40 to130mV in decrements of10mV) are
shown.Cellswere transfectedwithHCN1alone (left trace) or co-transfectedwithbothHCN1andTRIP8b(1a-2-4)mutants as indicated.B, shown is aquantitative
summary of Ih density in HEK293 cells co-transfected with HCN1 and TRIP8b(1a-2-4) mutants. ** and ***, p 0.01 and 0.001, respectively, compared with the
current density of HCN1when expressed alone. and, p 0.01 and 0.001, respectively, comparedwith currents obtained upon transfection of HCN1
with wild type TRIP8b(1a-2-4). No. of cells is indicated per experimental group on the bar histogram.
TABLE 3
Biophysical properties of Ih in the presence of various TRIP8b(1a-2-4) mutants
Biophysical properties of Ih in HEK293 cells co-transfected with HCN1 and various TRIP8b(1a-2-4) mutants are shown. Differences in current density were assessed using
Kruskal-Wallis test (p 0.001) followed by post hoc Mann-Whitney tests with a Dunn-Sidak correction. Other comparisons were made using ANOVA (p 0.001 for ;
p 0.01 for both V50 and k) with a post hoc Dunnett test. All data points are the mean	 S.E.
Construct Ih density  at110 mV V50 Slope factor/k
pA/pF ms mV
HCN1 7.4	 1.7 132	 14 80.1	 0.8 5.2	 0.3
(n
 24) (n
 6) (n
 7) (n
 7)
HCN1TRIP8b(1-a2-4) 33.8	 5.4a 182	 8 b 84.0	 0.8c 5.2	 0.2
(n
 23) (n
 14) (n
 15) (n
 15)
HCN1 19.4	 4.3 200	 10b 86.6	 1.4b 5.8	 0.2
TRIP8b(1a-2–4)TPR3-N13A (n
 25) (n
 8) (n
 7) (n
 7)
HCN1 24.1	 4.3b 144	 8 80.1	 0.8 6.2	 0.2
TRIP8b(1a-2–4)58 (n
 18) (n
 9) (n
 10) (n
 10)
HCN1 9.2	 0.9 144	 11 80.2	 1.0 6.4	 0.4c
TRIP8b(1a-2–4)58TPR3-N13A (n
 22) (n
 8) (n
 6) (n
 6)
a p 0.001.
b p 0.01.
c p 0.05.
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permeabilizedHEK293T cells cotransfectedwith eGFP and dif-
ferent combinations of TRIP8b mutant constructs and HCN1.
As shown in Fig. 3,A and B, wild type TRIP8b greatly increased
the surface expression of HCN1 (p 0.001). Both TRIP8b(1a-
2-4)[58] and TRIP8b(1a-2-4)[TPR3-N13A] significantly up-
regulated theHCN1 surface expressionTRIP8b(1a-2-4)[TPR3-
N13A] versus HCN1 p  0.001; TRIP8b(1a-2-4)[58] versus
HCN1 p 0.05), albeit less than wild type TRIP8b. By contrast,
in cells co-transfected with mutant TRIP8b lacking both NC
andTTbinding sites,HCN1 surface expression levelswere sim-
ilar to transfection with HCN1 alone. These flow cytometry
results were confirmed using co-immunoprecipitation of aHA-
tagged HCN1 in non-permeabilized HEK293T cells co-trans-
fected with different TRIP8b constructs. Consistent with flow
cytometry results, the wild type and singly mutated TRIP8b
[TRIP8b(1a-2-4)[58] or TRIP8b(1a-2-4)[TPR3-N13A]) sig-
nificantly increased the surface expression of HCN1 as com-
pared with control HCN1 alone (p  0.001), whereas TRIP8b
1a-2-4 harboring both mutations did not (Fig. 3, C and D).
Interaction with the CNBD Domain Is Required for TRIP8b-
induced Inhibition of HCNChannel Opening—Previous studies
have demonstrated an inhibitory effect of TRIP8b on HCN
FIGURE 3. TRIP8b interaction with either the HCN1 CNBD or the C-terminal tripeptide is required for TRIP8b-mediated increases in HCN1 surface
expression. A, shown are representative flow cytometric histograms obtained for cells labeled with surface-HA when a construct encoding HCN1-HA was
co-expressedwith eGFP alone or with eGFP and the indicated TRIP8b(1a-2-4) constructs. The x axis indicates the fluorescence intensity in arbitrary units (note
the log scale), and the y axis indicates the percentage of themaximum cell count. Representative distributions obtained from eGFP-transfected cells (control)
were overlaid with each experimental condition as indicated. B, summary data for flow cytometric studies of surface expression of HCN1-HA are shown.
Compared with HCN1 alone, TRIP8b(1a-2-4), TRIP8b(1a-2-4)[TPR3-N13A], and TRIP8b(1a-2-4)[58] significantly increased the HCN1 surface expression,
whereas TRIP8b(1a-2-4)[58TPR3-N13A] hadnoeffect (***,p0.001; *,p0.05,n
6).C, representativeWesternblots of extracts fromHEK293T cells transfected
withHCN1and the indicatedTRIP8bconstructs. SurfaceHAepitopewasbound innon-permeabilizedcellsbefore solubilizationand immunoprecipitationwith-HA.
D, summary data for surface HCN1-HA immunoprecipitation are shown. Compared with HCN1 alone, wild type TRIP8b(1a-2-4), TRIP8b(1a-2-4)[TPR3-N13A], and
TRIP8b(1a-2-4)[58] significantly increased the amount of HCN1 surface expression, whereas TRIP8b(1a-2-4)[58TPR3-N13A] had no effect (***, p 0.001, 1-way
ANOVAwith Tukey’s post hoc-test, n
 3). Inputwas 6%of total lysate, and immunoprecipitationwas 15%.Molecularmassmarkers are shown in kDa.
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channel gating that is manifested in slower activation time con-
stants () and a hyperpolarizing shift of the voltage-activation
curve (assessed as the voltage of half-maximal activation, V50)
(9–11). Because the CNBD domain is known to play an impor-
tant role in the regulation of HCN channel gating (5, 6) and
because TRIP8b antagonizes effects of cAMP on HCN2 chan-
nel function (9), we tested if direct and specific interactions
with the CNBD domainmediate the effects of TRIP8b on HCN
channel voltage dependence and kinetics.
Confirming previous results (10, 11), co-transfection of
HEK293 cells with HCN1 and wild type TRIP8b(1a-2-4)
resulted in significantly slowed Ih activation kinetics (Fig. 4)
accompanied by a hyperpolarizing shift of the activation
curve (Fig. 5, see also Table 3). The 58 mutation, which
eliminates TRIP8b binding to the CNBD domain, abolished
the inhibitory effect of TRIP8b on Ih gating as both the acti-
vation kinetics and the voltage-activation were comparable
with Ih in cells that were transfected with HCN1 alone (Figs.
4 and 5). In contrast, co-transfection of HCN1 with
TRIP8b(1a-2-4)[TPR3-N13A] exerted an inhibitory effect
on both Ih kinetics and voltage-dependent activation, similar
to the effect of wild type TRIP8b(1a-2-4). Finally, co-trans-
fection of HCN1 with the double mutant TRIP8b(1a-2-
4)[(58TPR3-N13A] yielded similar kinetics and voltage-
activation properties to those obtained when HCN1 was
expressed either alone or along with the 58 mutant. Taken
together, these results indicate that whereas current density
can be up-regulated by interaction of TRIP8b with either of
the two interaction sites on the HCN channel, the effects on
channel activation and kinetics are mediated solely by inter-
actions with the CNBD domain.
cAMP Inhibits TRIP8b Interaction with the HCN CNBD—The
direct interaction of TRIP8b with the HCN1 CNBD to affect
channel activation is consistent with prior findings suggest-
ing that TRIP8b is a competitive antagonist of the functional
effects of cAMP on HCN2 activation (9). To determine
whether cAMP directly antagonizes the interaction between
TRIP8b and the HCN CNBD, we performed GST pulldown
assays in the presence of cAMP concentrations from 0 to 1
mM, a range that includes concentrations below and above
saturation of cAMP effects on Ih voltage gating (18) (Fig. 6, A
and B). Graded concentrations of cAMP did not significantly
impair the interaction of TRIP8b with an HCN1 construct
containing an intact C-terminal tripeptide. However,
increasing amounts of cAMP reduced the binding of TRIP8b
to an HCN1 construct lacking the C-terminal tripeptide in a
concentration-dependent manner, with an IC50 of 40 nM
(n 
 3). This inhibition of TRIP8b binding to the HCN1
CNBD by cAMP indicates that TRIP8b and cAMP might
compete at overlapping binding sites to regulate HCN chan-
nel gating.
The crystal structure ofmouseHCN2 has demonstrated that
cAMP interacts directly with the highly conserved Arg-591
(Arg-538 in HCN1) within the CNBD, leading to allosteric
changes coupled to gating (5, 19, 20). Mutation of HCN1 Arg-
538 (or HCN2 Arg-591) to glutamate (HCN1[R538E]) elimi-
nates the effects of cAMP on channel function without altering
the ability of channels to be regulated by voltage (5). If TRIP8b
and cAMP compete for binding to the same site in the CNBD,
we reasoned that R538E mutation might prevent TRIP8b
binding. We performed a directed yeast-two hybrid assay
between TRIP8b(1a-2-4) and an HCN1 CNBD construct
harboring the R538E mutation (HCN1-(386–591)[R538E])
and found the R538E mutation indeed blocked binding of
TRIP8b to the CNBD (Table 4).
To confirm this finding, we also performed GST pulldown
assays. We purified a full-length TRIP8b construct that
included the CNBD binding domain (GST-TRIP8b(1a)) as well
as a construct lacking the 58 amino acids required for CNBD
binding (GST-TRIP8b(1c)). We then performedWestern blot-
ting afterGSTpulldown fromextracts prepared fromHEKcells
transfected with wild type HCN1, HCN1[R538E], HCN1[3],
and double mutant HCN1[3R538E] (Fig. 6C). In agreement
with yeast two-hybrid results, immunoblotting for HCN1 dem-
onstrated markedly decreased binding between TRIP8b(1a)
andHCN1[3R538E].We also performed a similarGSTpull-
down of cells transfected with HCN2, HCN2[R591E],
HCN2[3], and double mutant HCN1[3R591E] and also
observedmarkedly decreased binding betweenTRIP8b(1a) and
HCN1[3R591E] (supplemental Fig. 2). Taken together,
these data indicate thatHCN1Arg-538 (Arg-591 inHCN2)was
required for the binding of both TRIP8b and cAMP, suggesting
that their binding sites at the HCN CNBD overlap.
Because the overall structure of the CNBD, including the
importance of a critical Arg for cAMP binding, is shared by
other cyclic nucleotide-binding proteins (supplemental Fig.
3 and Flynn et al. (21)), we wondered if TRIP8bmight bind to
other cyclic nucleotide-gated channels. In directed yeast
two-hybrid studies, although TRIP8b interacted with the
CNBD of all HCN subunits (Fig. 1A), it did not interact with
the CNBD of olfactory or retinal cyclic nucleotide gated
channels CNGA1–4, CNGB1, or CNGB3, nor did it bind the
CNBD of the ether-a-go-go-like K channel subunit,
KCNH1 (Table 4). TRIP8b also failed to interact with the
CNBD of the sea urchin HCN channel, SpIH. These results
suggest that the presence of the critical Arg is required but
not sufficient to define an overlapping binding site of
TRIP8b and cAMP in the CNBD of cyclic-nucleotide regu-
lated K channels. This implies that TRIP8b-mediated inhi-
bition of cAMP effects may not be a general phenomenon in
this group but may rather be specific for vertebrate HCN
channels.
cAMP Regulates TRIP8b-mediated Effects on HCN1
Trafficking—Previous studies demonstrated that increasing
cAMP levels reverses TRIP8b inhibition of HCN2 gating and
kinetics (9). Because we found that TRIP8b interactionwith the
HCN CNBD affected both channel activation and trafficking,
we tested if dissociation of the TRIP8b/HCN1 interaction by
cAMPmight impair the effects ofTRIP8bon surface expression
of the HCN1 subunit. We performed flow cytometry studies in
untreated HEK293 cells and HEK293 cells treated with forsko-
lin to increase intracellular cAMP levels, evaluating surface
HCN1 expression in cells transfected alone or together with
TRIP8b constructs. As shown in Fig. 6D, forskolin treatment
had little effect on HCN1 surface expression when the channel
was expressed alone (30% reduction, n 
 6) or when coex-
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pressed with wild type TRIP8b(1a-2-4) (20% reduction, n
 6).
However, when coexpressed with a TRIP8b molecule that
increases HCN1 surface expression only via interaction with
the CNBD, TRIP8b(1a-2-4)[TPR3-N13A], forskolin reduced
HCN1 surface expression by 80% (n 
 6, p  0.001 versus
HCN1). These results are intriguing because they indicate that
cAMP and TRIP8b directly compete for a CNBD site that gov-
erns channel surface expression.
DISCUSSION
The principal findings of these studies are 1) TRIP8b func-
tions as an auxiliary subunit of HCN channels by interacting
FIGURE 4.SlowingofHCN1activationkineticsbyTRIP8b ismediatedexclusivelyby interactionwith theCNBD interactiondomain.A–D, Ih activationkinetics
in HEK293 cells expressing HCN1 and various mutants of TRIP8b(1a-2-4) are shown. Gray data points represent the activation kinetics of HCN1 when transfected
withoutTRIP8b(thesameinall fourpanels),andblackdatapoints representtheactivationkineticswhenHCN1wasco-transfectedwithvariousTRIP8b(1a-2-4)mutants,
as indicated. Insetsareexample traces comparing Ih (evokedbyahyperpolarizing step to110mV) in thepresence (black) andabsence (gray) of the indicatedTRIP8b
mutant.Only the first 500msof the response are shown. E, comparisonof all traces is shown in the insets topanel A-D. The currentswerenormalized to theamplitude
at the end of the pulse (3 s) and are presented at logarithmic scale for demonstration purposes. Statistical comparison of time constants at specific voltages to their
counterparts in control cells was performed using ANOVA followed byDunnett’s post hoc test; n
 6–15 cells per data point. *
 p 0.05; **
 p 0.01.
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with HCN1–4 subunits in a complex manner that involves at
least two distinct domains to modulate selectively gating and
surface expression, 2) whereas HCN surface expression is gov-
erned by TRIP8b binding to both the HCN CNBD and the
C-terminal tripeptide binding domains, modulation of gating is
dependent on the interaction with the CNBD site alone, and 3)
direct binding ofTRIP8b and cAMP to theHCNCNBDdomain
leads to competitive modulation of HCN channel surface
expression.
The original identification of TRIP8b as an HCN channel-
interacting partner identified the TPR/tripeptide interaction
site and also revealed the importance of this interaction for
FIGURE 5. The hyperpolarizing shift in the voltage activation of HCN1 channels by TRIP8b is mediated solely by interaction of HCN1 with the CNBD
interaction domain. A, activation curves are based on Ih recorded in HEK293 cells expressing HCN1 together with different TRIP8b mutants as indicated.
Deletion of the CNBD-interacting domain (58) resulted in a voltage activation curve not different from the one obtained when HCN1 is transfected alone,
whereas interference with the C-terminal -tripeptide interacting domain (TPR3-N13A) resulted in a hyperpolarizing shift of the activation curve similar to that
obtained with wild type TRIP8b(1a-2-4). For illustration purposes, the curves presented in this figure are based on grouped and normalized data, whereas
statistical analysis of V50 and the slope factor was performed on the parameters obtained from the individual Boltzmann fits. B, shown is quantification of the
effects of mutations on the shift in half-maximal activation V50. See Table 3 for values and statistical significance.
FIGURE 6. cAMPdisrupts TRIP8b-CNBD interactions and their functional effects. A and B, Western blots fromGST pulldown experiments are shown. Input
is 15% of lysate precipitated. A, extracts from HEK293T cells transfected with HCN1 (left panels) or HCN13 (right panels) were incubated with purified
recombinant TRIP8b(1a)-GST alone or with the indicated concentration of cAMP, then precipitated with immobilized glutathione and probed for HCN1 (top
panels) or TRIP8b (bottom panels). B, shown are summary data for cAMP disrupting TRIP8b-CNBD interaction. Values reflect density of bands corresponding to
HCN1 constructs precipitated by TRIP8b(1a)-GST, normalized to conditions lacking cAMP. C, extracts from HEK293T cells transfected with HCN1, HCN1[3],
HCN1[R538E], or HCN1[3R538E] were incubated with purified recombinant GST alone, TRIP8b(1a)-GST, or TRIP8b(1c)-GST, then precipitated with immo-
bilized glutathione and probed for HCN1.D, shown are summary data for flow cytometric studies of surface expression of HCN1-HA obtained for cells labeled
with surface-HA. Cells were transfectedwith a construct encoding HCN1-HA and eGFP alone or with eGFP and the indicated TRIP8b(1a-2-4) constructs. Before
flow cytometry, cells were incubated with or without forskolin as indicated.
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mediating the trafficking effects of a TRIP8b isoform,
TRIP8b(1b-2), that resulted in a down-regulation of HCN
channel function (22). Here we find that a TRIP8b isoform that
enhances HCN function, TRIP8b(1a-2-4), also employs the
TPR/tripeptide interaction in regulating channel trafficking.
Importantly, the current study identifies a second binding site
involving the TRIP8b residues N-terminal to the TPR domains
and the HCN CNBD that is also important for TRIP8b-medi-
ated regulation of HCN1 trafficking. Thus, only when both
interactions were eliminated did we block TRIP8b-mediated
up-regulation of HCN surface expression.
In addition to contributing to TRIP8b-mediated effects on
channel trafficking, we find that this second interaction site
alone regulates TRIP8b effects on HCN1 gating. Prior studies
demonstrated that TRIP8b acts as a competitive antagonist of
cAMP function on HCN2 gating (9). We show here that the
mechanism for TRIP8b antagonism of cAMP effects is via
direct binding to the CNBD. We found that the interaction
between TRIP8b and the CNBD was competitively blocked by
increasing concentrations of cAMP and that the concentration
at which cAMP inhibited 50% of TRIP8b binding to the HCN1
CNBD (40 nM) was similar to that reported for shifting the t1⁄2 of
Ih mediated by HCN1 in oocytes (60 nM) (5). These data are
consistent with the possibility that TRIP8b binds to and stabi-
lizes the non-cAMP bound CNBD conformation, whereas con-
formational changes induced by cAMP (19) eliminate TRIP8b
binding. Alternatively, TRIP8b and cAMPmight share overlap-
ping binding sites. Along these lines, mutation of a conserved
Arg residue in the HCN1 or HCN2 CNBD demonstrated that
this residue was necessary for both cAMP and TRIP8b binding.
Crystallization of the CNBD in the presence of TRIP8b should
help resolve the structural mechanisms by which cAMP and
TRIP8b compete at the CNBD.
Although we found TRIP8b interacted with the CNBDs of
HCN1-HCN4, it is important to note that TRIP8b did not bind
the CNBD of CNG channel subunits, suggesting that TRIP8b is
not a general antagonist of cAMP effects on CNBD-containing
proteins. It is also notable that TRIP8b did not bind the CNBD
of the sea urchin HCN subunit, SpIH. SpIH and other inverte-
brate HCN channel proteins (i.e. fruit fly, spiny lobster, honey-
bee, Egyptian mosquito) show tremendous diversity in their C
termini and all lack the tripeptide SNL conserved across most
vertebrate HCN channels. These observations suggest that an
important role for TRIP8b in HCN channel function evolved
more recently and is consistent with the gene encoding TRIP8b
(Pex5l) being present only in chordates. Nonetheless, further
studies will be required to determine whether TRIP8b is spe-
cific for antagonizing cAMP effects only on vertebrate HCN
channels.
Intriguingly, we find that the interaction between TRIP8b
and the HCN1 CNBD contributed to the trafficking effects of
TRIP8b on the HCN channel. Also surprising was the observa-
tion that forskolin was able to regulate the trafficking effects of
TRIP8b in a TRIP8b construct that interacted only with the
HCN CNBD domain. It remains unclear whether cAMPmight
play a role in regulating trafficking of HCN channels in the
brain, where neuronal activity that typically augments cellular
cAMP levels promotes HCN1 membrane expression (23).
TRlP8bmay facilitate HCN channel internalization via interac-
tions with adapter proteins such as AP-2 (11), and it is interest-
ing to speculate that cAMP in neurons might contribute to
dissociation of TRlP8b from HCN channels and increase their
surface expression. Future experiments are planned to evaluate
further the role cAMP might play in regulating TRlP8b-medi-
ated trafficking effects in vivo.
In summary, the results of our study give insight into the
functional importance of two distinct interactions between
HCN1–4 subunits and TRIP8b. Whereas both interactions
contribute to TRIP8b regulation of current density and intra-
cellular trafficking, unique interaction with the HCN CNBD
allows TRIP8b to regulate gating. Our data further suggest that
regulation ofHCNchannel function byTRIP8b is closely linked
to cAMP metabolism, as cAMP antagonizes the effects of
TRIP8b onHCN function by directly disrupting the interaction
between TRIP8b and the HCN CNBD.
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